ECSP024402A - Anticuerpos para mcp-1 humana - Google Patents

Anticuerpos para mcp-1 humana

Info

Publication number
ECSP024402A
ECSP024402A EC2002004402A ECSP024402A ECSP024402A EC SP024402 A ECSP024402 A EC SP024402A EC 2002004402 A EC2002004402 A EC 2002004402A EC SP024402 A ECSP024402 A EC SP024402A EC SP024402 A ECSP024402 A EC SP024402A
Authority
EC
Ecuador
Prior art keywords
antibodies
mcp
human mcp
eotaxin
cdr2
Prior art date
Application number
EC2002004402A
Other languages
English (en)
Inventor
Peter Hiestand
Franco Padova
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP024402A publication Critical patent/ECSP024402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan moléculas de enlace de MCP-1 que comprenden cuando menos un dominio variable de cadena pesada e inmunoglobulina (VH), el cual comprende las regiones hipervariables CDR1, CDR2, y CDR3 de la secuencia definida, para utilizarse en el tratamiento de enfermedades o desórdenes mediados por MCP-1 o eotaxina.
EC2002004402A 2000-06-30 2002-12-24 Anticuerpos para mcp-1 humana ECSP024402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP024402A true ECSP024402A (es) 2003-02-06

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004402A ECSP024402A (es) 2000-06-30 2002-12-24 Anticuerpos para mcp-1 humana

Country Status (27)

Country Link
US (1) US20040047860A1 (es)
EP (1) EP1299421B1 (es)
JP (2) JP3920215B2 (es)
KR (1) KR100603899B1 (es)
CN (1) CN100486996C (es)
AR (1) AR046379A1 (es)
AT (1) ATE426616T1 (es)
AU (2) AU2001283903B2 (es)
BR (1) BR0112086A (es)
CA (1) CA2412775A1 (es)
CZ (1) CZ20024256A3 (es)
DE (1) DE60138102D1 (es)
EC (1) ECSP024402A (es)
ES (1) ES2322643T3 (es)
GB (1) GB0016138D0 (es)
HU (1) HUP0301477A3 (es)
IL (1) IL153721A0 (es)
MX (1) MXPA03000201A (es)
NO (1) NO20026063L (es)
NZ (1) NZ523195A (es)
PE (1) PE20020125A1 (es)
PL (1) PL207133B1 (es)
PT (1) PT1299421E (es)
RU (1) RU2314316C2 (es)
SK (1) SK18122002A3 (es)
WO (1) WO2002002640A2 (es)
ZA (1) ZA200300199B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
CA2468733C (en) 2001-11-30 2013-06-11 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
JP4426449B2 (ja) * 2002-09-12 2010-03-03 財団法人化学及血清療法研究所 ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント
WO2005044200A2 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
TW200716174A (en) * 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
WO2007147026A2 (en) * 2006-06-15 2007-12-21 Centocor, Inc. Ccr2 antagonists for chronic organ transplantation rejection
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CN101616689A (zh) * 2006-10-05 2009-12-30 森托科尔奥索生物科技公司 用于治疗纤维化的ccr2拮抗剂
CA2672944A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
CN101827610A (zh) * 2007-06-29 2010-09-08 森托科尔奥索生物科技公司 抗mcp-1抗体、组合物、方法和用途
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
ES2658117T3 (es) 2008-08-18 2018-03-08 Pfizer Inc. Anticuerpos anti-CCR2
CA2734800C (en) 2008-08-20 2021-02-09 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
RU2014144463A (ru) * 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
WO2016025789A1 (en) * 2014-08-15 2016-02-18 PixarBio Corporation Compositions for inhibting inflammation in a subject with a spinal cord injury and methods of using the same
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
BR112021020525A2 (pt) 2019-04-17 2021-12-14 Chugai Pharmaceutical Co Ltd Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114867532A (zh) * 2019-12-18 2022-08-05 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019552D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
EP1299421B1 (en) 2009-03-25
SK18122002A3 (sk) 2003-06-03
WO2002002640A2 (en) 2002-01-10
PE20020125A1 (es) 2002-03-12
NO20026063L (no) 2003-02-27
CZ20024256A3 (cs) 2003-04-16
GB0016138D0 (en) 2000-08-23
JP3920215B2 (ja) 2007-05-30
AR046379A1 (es) 2005-12-07
KR100603899B1 (ko) 2006-07-25
BR0112086A (pt) 2003-05-06
WO2002002640A3 (en) 2002-05-16
ES2322643T3 (es) 2009-06-24
EP1299421A2 (en) 2003-04-09
DE60138102D1 (de) 2009-05-07
NO20026063D0 (no) 2002-12-17
JP2004502421A (ja) 2004-01-29
CA2412775A1 (en) 2002-01-10
HUP0301477A3 (en) 2005-11-28
PT1299421E (pt) 2009-06-26
IL153721A0 (en) 2003-07-06
AU8390301A (en) 2002-01-14
JP2007054079A (ja) 2007-03-08
CN100486996C (zh) 2009-05-13
HUP0301477A2 (hu) 2003-08-28
PL359854A1 (en) 2004-09-06
NZ523195A (en) 2005-09-30
ATE426616T1 (de) 2009-04-15
MXPA03000201A (es) 2003-05-27
CN1443199A (zh) 2003-09-17
KR20030014272A (ko) 2003-02-15
PL207133B1 (pl) 2010-11-30
AU2001283903B2 (en) 2005-06-02
ZA200300199B (en) 2003-11-13
RU2314316C2 (ru) 2008-01-10
US20040047860A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
ECSP024402A (es) Anticuerpos para mcp-1 humana
AR035581A1 (es) Anticuerpos para il-1beta humana
GEP20074222B (en) Antibodies to cd40
PE20110797A1 (es) Anticuerpos anti mn
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
NO20064788L (no) Anti-myostatin-anistoffer
CY1115875T1 (el) Αντισωματα toy υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
NZ595235A (en) Compositions and methods for increasing muscle growth
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA200801065A1 (ru) Антимиостатиновые антитела
CL2010000790A1 (es) Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).
EA201100694A1 (ru) Антитело к cd38 человека и его применение
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
BR0207151A (pt) Moléculas de aglutinação terapêuticas
MA40913A (fr) Conjugués anticorps-médicament
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
DK1100829T3 (da) Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης